Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Rating) VP Tami Tillotson Martin sold 5,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $32.98, for a total value of $164,900.00. Following the completion of the transaction, the vice president now owns 87,220 shares in the company, valued at $2,876,515.60. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Supernus Pharmaceuticals Stock Down 2.0 %
Supernus Pharmaceuticals stock opened at $32.16 on Friday. The stock’s 50 day moving average price is $29.18 and its 200 day moving average price is $29.81. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.00 and a quick ratio of 1.69. The company has a market cap of $1.72 billion, a PE ratio of 24.74 and a beta of 1.04. Supernus Pharmaceuticals, Inc. has a 1-year low of $23.15 and a 1-year high of $34.50.
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) last posted its earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.15). The firm had revenue of $170.10 million for the quarter, compared to analysts’ expectations of $164.23 million. Supernus Pharmaceuticals had a return on equity of 9.05% and a net margin of 12.20%. The firm’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.43 earnings per share. On average, sell-side analysts predict that Supernus Pharmaceuticals, Inc. will post 1.64 EPS for the current fiscal year.
Institutional Trading of Supernus Pharmaceuticals
Analyst Ratings Changes
A number of analysts recently weighed in on the company. StockNews.com upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, April 18th. TheStreet downgraded Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Monday, April 18th.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.
- Get a free copy of the StockNews.com research report on Supernus Pharmaceuticals (SUPN)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.